Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityLiabilities and Shareholders EquityOther Non-Current LiabilitiesPayablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Greenwich LifeSciences (GLSI) Retained Earnings (2019 - 2025)

Greenwich LifeSciences filings provide 7 years of Retained Earnings readings, the most recent being -$77.6 million for Q3 2025.

  • Quarterly Retained Earnings fell 33.51% to -$77.6 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$77.6 million through Sep 2025, down 33.51% year-over-year, with the annual reading at -$66.2 million for FY2024, 31.35% down from the prior year.
  • Retained Earnings hit -$77.6 million in Q3 2025 for Greenwich LifeSciences, down from -$73.4 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$29.7 million in Q1 2021 and bottomed at -$77.6 million in Q3 2025.
  • Average Retained Earnings over 5 years is -$48.3 million, with a median of -$45.2 million recorded in 2023.
  • The largest annual shift saw Retained Earnings fell 12.04% in 2021 before it crashed 33.51% in 2025.
  • Greenwich LifeSciences' Retained Earnings stood at -$33.6 million in 2021, then dropped by 23.26% to -$41.5 million in 2022, then dropped by 21.44% to -$50.4 million in 2023, then plummeted by 31.35% to -$66.2 million in 2024, then dropped by 17.29% to -$77.6 million in 2025.
  • Per Business Quant, the three most recent readings for GLSI's Retained Earnings are -$77.6 million (Q3 2025), -$73.4 million (Q2 2025), and -$69.4 million (Q1 2025).